The aim of the LifeMatrix platform, funded by SwissTransMed ( is the clinical translation (First-In-Man) of novel “off-the-shelf” tissue engineered homologous matrices with the capacity of growth and regeneration to repair congenital heart disease. Specifically, First-In-Man clinical studies with tissue engineered vascular grafts and tissue patches will be initiated. The highly interdisciplinary LifeMatrix consortium (basic scientists, biomedical engineers, translational researchers, and clinicians) is centered around three sequentially integrated infrastructure and knowledge platforms: (a) Matrix-On-The-Chip platform (ETH, Health Science Technology); (b) GMP Clinical Translational Platform (UZH, Swiss Center for Regenerative Medicine); (c) Clinical Pilot Study Platform (UZH, Children’s Hospital, SwissPednet).